BSE filing, NSE: ISHITADR. Summary written from the filing by ALFA Finder's alert engine.
Ishita Drugs & Industries Ltd: key numbers
- Share price
- ₹73.80
- Market cap
- ₹22.07 Cr
- Revenue (annual)
- ₹14.66 Cr
- Net profit (annual)
- ₹0.78 Cr
- P/E (TTM)
- 31.2×Sector 46.1×
- Promoter holding
- 50.04%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ishita Drugs & Industries Ltd
All →Ishita Drugs & Industries Board Meeting Date
Ishita Drugs & Industries will hold a board meeting on 03/11/2026 to approve Q1 FY2027 unaudited results. The filing is a prior intimation under Regulation 29 of SEBI LODR.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd submitted its quarterly shareholding pattern under Regulation 31, disclosing the promoter and public shareholdings as of September 30, 2026.
Ishita Drugs & Industries Management Change
Ishita Drugs and Industries Limited has re-appointed Mrs. Abha Agrawal as a Non-Executive Non-Independent Director. The company also re-appointed M/s. Jaymin Shah & Associates as Statutory Auditors.
Ishita Drugs & Industries Other Announcement
Ishita Drugs & Industries Ltd has re-appointed M/s. Jaymin Shah & Associates as its Statutory Auditor from the 33rd to the 34th AGM.
Ishita Drugs & Industries Annual General Meeting
Ishita Drugs & Industries Ltd. held its 33rd Annual General Meeting on September 30, 2026. The meeting covered financial statements, auditor appointments, and director re-appointment.
Ishita Drugs & Industries Debt & Borrowing: ₹11.75 Cr
Ishita Drugs approved Rs.11.75 Crore borrowings from HDFC Bank, covering a term loan and working capital facility. This is within shareholder-approved borrowing limits from its 31st AGM.
- Value
- ₹11.75 Cr
Other other announcement announcements
All →Visaka Industries Other Announcement
Visaka Industries informed the exchange about sending reminder letters to shareholders regarding the compulsory transfer of unclaimed dividends and equity shares to the IEPF account.
Arvaya Healthcare Other Announcement
Arvaya Healthcare filed its quarterly shareholding pattern under Regulation 31(1)(c). The filing reports routine ownership breakdowns with no transaction.
AYM Syntex Other Announcement
AYM Syntex's board appointed BSR & Co. LLP as statutory auditor for five years, subject to shareholder approval. Routine auditor appointment; no monetary value involved.
- Execution
- Five consecutive years, from the conclusion of the 44th AGM to the conclusion of the 49th AGM
Kalpataru Other Announcement
Kalpataru filed CARE Ratings' IPO monitoring report for the quarter ended September 30, 2026. It reports no deviation from offer objects, though fund co-mingling was noted.
Rnit AI Solutions Other Announcement
RNIT AI Solutions filed its quarterly Reg 32 statement for the preferential issue. It reports no deviation in use of funds.
Persistent Systems Other Announcement
Persistent Systems filed its shareholding pattern for 26 October 2026, reflecting the increase in paid-up capital from its QIP allotment. The filing shows the post-allotment shareholding split.